Sendero Wealth Management LLC Buys New Stake in Icon Plc $ICLR

Sendero Wealth Management LLC purchased a new position in shares of Icon Plc (NASDAQ:ICLR - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,601 shares of the medical research company's stock, valued at approximately $2,415,000.

Other institutional investors have also modified their holdings of the company. NBC Securities Inc. purchased a new stake in shares of Icon in the 1st quarter valued at $59,000. Farther Finance Advisors LLC boosted its holdings in Icon by 22.8% during the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock valued at $99,000 after acquiring an additional 110 shares during the period. Handelsbanken Fonder AB grew its position in Icon by 25.3% in the 1st quarter. Handelsbanken Fonder AB now owns 25,905 shares of the medical research company's stock valued at $4,533,000 after acquiring an additional 5,229 shares in the last quarter. Wealthquest Corp purchased a new stake in Icon during the first quarter worth about $862,000. Finally, Transcend Capital Advisors LLC lifted its position in shares of Icon by 7.6% during the first quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company's stock worth $205,000 after purchasing an additional 83 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $193.89 on Monday. Icon Plc has a 52 week low of $125.10 and a 52 week high of $303.69. The company has a 50-day moving average price of $173.71 and a 200 day moving average price of $156.51. The company has a market cap of $15.66 billion, a P/E ratio of 19.95, a PEG ratio of 2.88 and a beta of 1.23. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35.

Icon (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The business had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the prior year, the business posted $3.75 EPS. The company's revenue for the quarter was down 4.8% on a year-over-year basis. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. Research analysts predict that Icon Plc will post 13.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ICLR. Rothschild & Co Redburn upgraded shares of Icon from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $184.00 to $236.00 in a report on Wednesday, September 3rd. Weiss Ratings reissued a "hold (c)" rating on shares of Icon in a research report on Saturday, September 27th. Citigroup reaffirmed a "neutral" rating and set a $200.00 price objective (down previously from $225.00) on shares of Icon in a research report on Thursday, August 21st. Jefferies Financial Group lowered Icon from a "buy" rating to a "hold" rating and decreased their target price for the company from $220.00 to $175.00 in a report on Tuesday, September 9th. Finally, Baird R W raised Icon from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $217.33.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.